Nasdaq:IVF
INVO Fertility, Inc.
A growth-stage fertility clinic operator driving revenue expansion through organic center openings and a rapidly scaling patient base in the North American market.
Key Metrics
Investment Thesis
Bull Case
INVO Fertility represents a compelling high-growth opportunity in the secularly expanding fertility care market, evidenced by triple-digit revenue growth and a rapidly improving path to profitability. The company's scalable business model and proprietary clinical protocols position it to capture significant market share as demand for fertility preservation services continues to rise post-pandemic.
Bear Case
Investors should exercise caution given the persistent net losses and negative operating cash flow, which indicate that the company has not yet achieved sustainable commercial viability. The heavy reliance on debt financing and substantial current liabilities relative to assets suggests elevated financial distress risk if revenue growth stalls or patient acquisition costs increase.
About INVO Fertility, Inc.
INVO Fertility, Inc. (IVF) is a leading provider of fertility preservation and treatment services, primarily serving patients in North America through its network of specialized reproductive endocrinology centers. The company focuses on offering comprehensive IVF cycles, egg freezing, and genetic testing to individuals and couples facing infertility or those seeking family planning options.
Analysis
Management Discussion
Financial performance has shown marked improvement with revenue surging from $0.8M to $6.5M over the last three years, narrowing the net loss significantly from -$10.9M in 2022 to just -$0.9M in 2024. Despite a current operating cash flow deficit of -$3.0M, the company has strengthened its balance sheet with a positive change in cash of $508,972 and reduced reliance on external financing as operations mature.
Industry Overview
The global fertility treatment market is experiencing robust growth driven by delayed childbearing trends, increased awareness of reproductive health, and technological advancements in assisted reproduction. This expanding industry provides a favorable tailwind for specialized operators like INVO Fertility, although it remains subject to intense competition and regulatory scrutiny regarding embryo research and egg freezing practices.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $822.2K | $3.0M | $6.5M |
| Cost of Revenue | $331.5K | $0 | $3.7M |
| Gross Profit | $490.7K | $3.0M | $2.8M |
| Operating Expenses | $11.1M | $9.8M | $14.7M |
| Operating Income | $-10.6M | $-6.8M | $-8.1M |
| R&D | $544.0K | $165.9K | $489.7K |
| G&A | $10.6M | $7.5M | $2.4M |
| Marketing | — | — | $37.5K |
| Stock-Based Comp | $1.6M | — | — |
| D&A | $77.3K | $200.9K | $919.6K |
| Depreciation | $44.6K | $80.3K | $102.1K |
| Amortization | $1.8K | $0 | $817.5K |
| Other OpEx | $0 | $2.1M | $11.7M |
| Non-Operating Income | $-263.2K | $-1.2M | $-993.3K |
| Interest Expense | $59.4K | $925.9K | $1.1M |
| Pre-Tax Income | $-10.9M | $-8.0M | $-9.1M |
| Income Tax | $2.9K | $27.8K | $-22.9K |
| Continuing Ops | $-10.9M | $-8.0M | $-9.1M |
| Discontinued Ops | $0 | $0 | $8.2M |
| Net Income | $-10.9M | $-8.0M | $-870.6K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-10.9M | $-8.0M | $-870.6K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $621.1K | $1.3M | $1.3M |
| Accounts Receivable | $77.1K | $140.6K | $174.9K |
| Inventory | $263.6K | $264.5K | $219.8K |
| Prepaid Expenses | $190.2K | $622.3K | $182.3K |
| Other Current Assets | $90.1K | $232.4K | $741.4K |
| Long-Term Assets | $3.5M | $19.6M | $45.1M |
| PP&E (Net) | $436.7K | $826.4K | $466.7K |
| Intangibles | — | $4.1M | $18.1M |
| Goodwill | — | $5.9M | $23.5M |
| Operating Leases | $1.8M | $5.7M | $2.3M |
| Other LT Assets | $1.2M | $2.2M | $0 |
| Total Assets | $4.1M | $20.9M | $46.4M |
| Current Liabilities | $3.4M | $8.2M | $17.9M |
| Current Leases | $231.6K | $397.6K | $239.1K |
| Other Current Liab | $3.2M | $7.8M | $17.7M |
| Long-Term Liabilities | $1.7M | $11.8M | $8.3M |
| LT Operating Leases | $1.7M | $5.5M | $2.2M |
| Other LT Liab | $1.9K | $6.3M | $6.1M |
| Total Liabilities | $5.1M | $20.0M | $26.2M |
| Shareholders' Equity | $-977.6K | $892.8K | $20.2M |
| Retained Earnings | $-49.8M | $-57.8M | $-67.2M |
| Total L&E | $4.1M | $20.9M | $46.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-10.9M | $-8.0M | $-870.6K |
| Non-Cash Adjustments | $3.2M | $1.8M | $-4.3M |
| Working Capital Changes | $1.1M | $1.5M | $2.2M |
| Cash from Operations | $-6.6M | $-4.8M | $-3.0M |
| Capital Expenditures | $10.8K | $444.7K | $183.7K |
| Cash from Investing | $-81.2K | $-2.5M | $363.9K |
| Cash from Financing | $1.1M | $7.4M | $3.1M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-5.6M | $142.3K | $509.0K |
| Beginning Cash | $5.7M | $90.1K | $232.4K |
| Ending Cash | $90.1K | $232.4K | $741.4K |
Frequently Asked Questions
How does INVO Fertility, Inc. make money?
The company's revenue is derived from its primary segment of reproductive medicine services, which includes in vitro fertilization (IVF) cycles, egg freezing procedures, and related laboratory testing. Additional revenue streams come from genetic testing services for embryos and ancillary medical products sold to partner clinics, reflecting a diversified approach within the fertility care value chain.
What are the main risks for IVF?
The company faces significant regulatory risks associated with the evolving landscape of reproductive medicine laws across different US states. Operating leverage remains a concern as fixed costs are high relative to current revenue levels, creating vulnerability if patient volumes do not grow proportionally. Additionally, reimbursement pressures from payers and potential changes in insurance mandates could impact pricing power and margin stability.
What is IVF's competitive advantage?
INVO Fertility leverages a proprietary network of high-volume reproductive endocrinology centers that benefit from economies of scale and specialized clinical expertise. The company maintains strong competitive positioning through its strategic focus on patient experience and technology-driven treatment protocols that improve success rates, while its concentrated geographic footprint allows for efficient operational management.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.